Should You Buy, Sell, or Hold PayPal Stock Before Q1 Earnings?
PYPL expects flat to low single-digit revenue growth on a currency-neutral basis for the to-be-reported quarter. Non-GAAP earnings are expected between $1.15 per share and $1.17 per share, suggesting 6-8% growth on a year-over-year basis.
The Zacks Consensus Estimate for first-quarter revenues is pegged at $7.83 billion, indicating an increase of 1.64% from the year-ago quarter's reported figure.
The consensus mark for earnings stands at $1.15 per share, down by a penny over the past 30 days, suggesting a decline of 17.86% from the figure reported in the year-ago quarter.
PayPal's earnings beat the Zacks Consensus Estimate in all the trailing four quarters, with an average surprise of 14.26%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Let's see how things have shaped up for the upcoming announcement.
Strong Portfolio, Rich Partner Base to Aid PYPL's Q1 Results
PYPL's first-quarter results are expected to reflect portfolio strength. Fastlane, which enhances the guest checkout experience by allowing users to complete their purchase in one click, remains noteworthy. Strong monetization efforts of Venmo are likely to have aided Total Payments Volume in the to-be-reported quarter.
PYPL's rich partner base, which includes Amazon AMZN, Shopify SHOP, Apple, Alphabet and Meta Platforms META, has been a key catalyst. The integration of PayPal and Venmo credit or debit cards into Apple Wallet has been a noteworthy development.
PayPal is now an additional processor for Shopify Payments in the United States. Its branded checkout solutions are now integrated into Shopify Payments. This creates a single and unified experience for business owners to drive operational efficiency. PayPal's partnership with Amazon now brings PayPal Checkout to SMBs, offering Buy with Prime. Its collaboration with Apple and Google to integrate the Venmo debit card with Apple Pay and Google Pay has been a noteworthy development.
PayPal is a top payment method for advertisers and consumers globally across Meta Platforms' family of apps. Creators and developers are using Hyperwallet. META also uses Braintree for credit card processing.
PayPal is expanding value-added services to boost the merchant experience. In the fourth quarter of 2024, PYPL launched FX-as-a-service, which is an automated currency conversion, and the platform is already live on Meta Platforms. PYPL's network tokens for automated billing capabilities are live with merchants, including Instacart, Mint Mobile and Poshmark. Expanding value-added services is expected to drive transaction margin in dollar terms. PayPal Everywhere, which was launched in September 2024, is driving significant increases in debit card adoption and opening new categories of spend.
PYPL Shares Underperform Sector, Industry
Paypal shares have declined 23.8% year to date, underperforming the Zacks Business Service sector's fall of 2.8% and the Zacks Internet Software Industry's drop of 0.8%.
PYPL Stock's Performance
Image Source: Zacks Investment Research
PayPal stock is cheap, as suggested by the Value Score of B.
In terms of the forward 12-month Price/Sales ratio, PYPL is trading at 1.91X, lower than the industry's 6.33X.
Price/Sales (P/S) Ratio
PayPal Benefits From Expanding Portfolio
Portfolio strength has been helping PayPal maintain deep and trusted relationships with merchants and consumers. Its two-sided platform helps develop direct financial relationships with customers and merchants. PYPL's investments in improving branded checkout, person-to-person (P2P) and Venmo helped in driving total active accounts.
Strong adoption of Fastlane is expected to boost future volumes as PYPL ink deals with NBCUniversal, Roku and StockX. PayPal expects transaction margin in dollar terms (ex-interest on customer balances) to grow at least 5% in 2025 and high-single-digit growth for 2027. Over the long term, this is expected to grow at more than 10%.
PYPL - Buy, Sell or Hold?
PayPal rides on the growing demand for peer-to-peer payments and digital wallets. Hence, investors who already own the stock may expect PYPL's growth prospects to be rewarding over the long term. However, PYPL's near-term prospects are full of challenges due to challenging macroeconomic conditions, unfavorable forex, and sluggish consumer spending.
PayPal currently has a Zacks Rank #3 (Hold), suggesting that it may be wise to wait for a more favorable entry point in the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN): Free Stock Analysis Report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
Shopify Inc. (SHOP): Free Stock Analysis Report
Meta Platforms, Inc. (META): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
Textron Q2 Earnings Surpass Estimates, Revenues Improve Y/Y
Textron reported second-quarter 2025 adjusted earnings of $1.55 per share, which beat the Zacks Consensus Estimate of $1.45 by 6.9%. The bottom line also rose 0.6% from $1.54 in the year-ago quarter. The company reported GAAP earnings of $1.35 per share, which remained flat year over year. Growth in revenues and segmental profit was fully offset by elevated expenses, leading to flat year-over-year earnings. TXT's Revenues The company reported total revenues of $3.72 billion, which beat the Zacks Consensus Estimate of $3.63 billion by 2.4%. Moreover, revenues increased 5.4% from the year-ago quarter's level of $3.53 billion. Manufacturing revenues improved 5.3% year over year to $3.70 billion. Segmental Performance of Textron Textron Aviation: Revenues from this segment increased 2.8% year over year to $1.52 billion. This was primarily driven by higher aftermarket parts and services revenues, in addition to increased aircraft revenues. Textron Aviation generated an operating profit of $180 million compared with $195 million in the year-ago period. This deterioration can be attributed to the unfavorable mix of aircraft sold and higher warranty costs. The segment delivered 49 jets, up from 42 in the year-ago quarter. It also delivered 34 commercial turboprops, down from 44 in the second quarter of 2024. Order backlog at the end of the quarter totaled $7.85 billion. Bell: Revenues from this segment amounted to $1,016 million, up 28% from the year-ago quarter's registered number. This was driven by increased military revenues, primarily related to the U.S. Army's MV-75 program, as well as higher commercial revenues. The segment's profit dropped 2.4% to $80 million due to higher research and development costs. Bell delivered 32 commercial helicopters, flat year over year. Its order backlog at the end of the quarter totaled $6.9 billion. Textron Systems: This segment's revenues amounted to $321 million, down 0.6% from the year-ago quarter's registered number. Profits totaled $40 million, up 14.3% from the prior-year figure. The improvement was primarily driven by lower selling and administrative expenses. Textron Systems' backlog at the end of the quarter totaled $2.2 billion. Industrial: Revenues from this segment declined 8.2% to $839 million due to lower sales volumes. Lower revenues from the Textron Specialized Vehicles unit, owing to the disposition of the Powersports business, also affected this unit's top line. Moreover, the segment's profit totaled $54 million compared with $42 million in the prior-year quarter. The improvement can be partially attributed to the benefit of cost reductions from restructuring activities. Textron eAviation: Revenues from the segment totaled $8 million, lower than the prior-year period's revenues of $9 million. It reported a loss of $16 million, narrower than a loss of $18 million incurred in the prior-year period. Finance: This segment's revenues increased 25% to $15 million. Its profit totaled $8 million compared with $7 million in the year-ago period. Textron's Financials As of June 28, 2025, cash and cash equivalents totaled $1.35 billion compared with $1.39 billion as of Dec. 28, 2024. Cash generated from operating activities in the first six months of 2025 amounted to $281 million compared with $353 million in the year-ago period. Capital expenditures amounted to $134 million (as of June 28) compared with $140 million in the prior-year period. The long-term debt totaled $3.04 billion as of June 28, 2025, compared with $2.89 billion as of Dec. 28, 2024. TXT's Guidance Textron reiterated its 2025 adjusted earnings per share (EPS) outlook. The company still expects adjusted EPS to be in the range of $6.00-$6.20. The Zacks Consensus Estimate for earnings is pegged at $6.13 per share, which lies above the mid-point of its guided range. TXT's Zacks Rank Textron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Recent Defense Releases Lockheed Martin CorporationLMT reported second-quarter 2025 adjusted earnings of $7.29 per share, which beat the Zacks Consensus Estimate of $6.49 by 12.3%. The bottom line increased 2.5% from the year-ago quarter's reported figure of $7.11. Net sales were $18.16 billion, which missed the Zacks Consensus Estimate of $18.56 billion by 2.2%. The top line, however, inched up 0.2% from $18.12 billion in the year-ago quarter. Northrop Grumman CorporationNOC reported second-quarter 2025 adjusted earnings of $7.11 per share, which beat the Zacks Consensus Estimate of $6.71 by 6%. NOC's total sales of $10.35 billion beat the Zacks Consensus Estimate of $10.06 billion by 2.9%. The top line also rose 1.3% from $10.22 billion reported in the year-ago quarter. RTX Corporation's RTX second-quarter 2025 adjusted EPS of $1.56 beat the Zacks Consensus Estimate of $1.45 by 7.6%. The bottom line also improved 10.6% from the year-ago quarter's level of $1.41 due to growth in adjusted operating profit. RTX's second-quarter sales totaled $21.58 billion, which surpassed the Zacks Consensus Estimate of $20.53 billion by 5.1%. The top line also surged a solid 9.4% from $19.72 billion recorded for the second quarter of 2024. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report This article originally published on Zacks Investment Research ( Zacks Investment Research
Globe and Mail
a day ago
- Globe and Mail
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
Boston Scientific Corporation BSX posted second-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 20.9% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 4.2% and also exceeded the company's adjusted earnings per share guidance range of 71-73 cents per share. The quarter's adjustments included certain amortization expenses, goodwill and other intangible asset impairment charges and acquisition/divestitures-related net charges, among others. Reported EPS for the second quarter was 53 cents, reflecting a 141% jump from the year-ago quarter's 22 cents. Q2 Revenue Details of BSX Revenues in the second quarter totaled $5.06 billion, up 22.8% year over year on a reported basis and 21.6% on an operational basis (at a constant exchange rate or CER). Organic growth, adjusted for foreign currency fluctuations and certain recent acquisitions and divestments, was 17.4%. The top line surpassed the Zacks Consensus Estimate by 2.3%. and exceeded the company's Q2 revenue forecast of 17%-19%. Following the earnings announcement, shares of BSX climbed 1.6% in pre-market trading today. BSX's Q2 Revenues by Regions In the second quarter, revenues rose 30.7% in the United States on a reported basis (same operationally). Reported revenues rose 6.8% in the Europe, Middle East and Africa (EMEA) region (up 1.8% operationally) and 18% in the Asia Pacific zone (up 15.4% operationally). Reported revenues increased 4% in Latin America and Canada (up 8.9% operationally). Reported revenue growth in emerging markets was 11.6% (up 12.1% operationally). Breaking Down BSX's Q2 Revenues by Segments Boston Scientific recently reorganized its operational structure and aggregated its core businesses into two reportable segments — MedSurg and Cardiovascular. Both these generate revenues from the sale of Medical Devices. MedSurg MedSurg revenues in the second quarter were $1.72 billion, up 15.7% year over year on a reported basis (up 7% organically). Within this, the Endoscopy unit generated revenues of $737 million, up 7.8% organically. Urology revenues were $679 million, reflecting organic growth of 6.3%. The Neuromodulation business reported $303 million in revenues, highlighting a 6.6% rise organically year over year. Cardiovascular The company generates maximum revenues from this segment. Revenues in the second quarter came in at $3.35 billion, up 26.8% (reported) and 23.2% (organic) year over year. Within this, Cardiology business sales totaled $2.65 billion (up 27.9% year over year organically) in the second quarter. The Peripheral Interventions unit generated $698 million in sales, up 7%. BSX's Margin Performance in Q2 The gross margin in the second quarter contracted 152 basis points (bps) year over year to 67.7%. There was a 28.9% rise in the cost of products sold to $1.63 billion in the reported quarter. Selling, general and administrative expenses rose 18.7% to $1.72 billion. Research and development expenses rose 37.3% to $526 million. Royalty expenses of $14 million increased 55.6% year over year. The adjusted operating margin contracted 148 bps to 23.1% in the reported quarter. BSX Updates 2025 Outlook, Shares Q3 View For 2025, Boston Scientific now anticipates net sales to grow approximately 18-19% (compared with the earlier guidance of 15-17%) on a reported basis and 14-15% on an organic basis (earlier 12-14%). The Zacks Consensus Estimate is currently pegged at $19.50 billion, indicating a 16.4% rise from the 2024 reported figure. Full-year adjusted EPS is expected in the range of $2.95-$2.99 (previously $2.87-$2.94). The Zacks Consensus Estimate for the same is currently pegged at $2.91. For the third quarter of 2025, revenue growth is projected in the range of approximately 17-19% on a reported basis (up 12-14% organically). Adjusted earnings are expected in the range of 70-72 cents per share. The Zacks Consensus Estimate for third-quarter earnings and revenues is pegged at 70 cents per share and $4.85 billion, respectively. Our View on BSX Stock Boston Scientific ended the second quarter of 2025 on a solid note, with both revenues and earnings beating the respective estimates. The performance reflected the strength of the company's product portfolio and the effectiveness of its highly engaged global team. Additionally, the raised sales and EPS guidance for the full year instill optimism. However, contraction of both margins in the quarter is concerning. Boston Scientific achieved several milestones across its portfolio in the second quarter. It gained FDA approval to expand the labeling of its FARAPULSE PFA System for treating drug-refractory, symptomatic persistent atrial fibrillation (AF) and began enrollment in the ReMATCH IDE trial to evaluate its FARAWAVE and FARAPOINT PFA catheters in patients with recurrent persistent AF. In Europe, the company secured CE Mark for the WATCHMAN FLX Pro device, designed to improve healing, visualization and anatomical fit. Boston Scientific also completed the acquisitions of Intera Oncology and SoniVie, strengthening its presence in liver cancer and hypertension treatment technologies. BSX's Zacks Rank and Other Key Picks Boston Scientific currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Cencora COR, Veeva Systems VEEV and Resmed RMD. Cencora, carrying a Zacks Rank #2, reported second-quarter fiscal 2025 adjusted EPS of $4.42, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $75.45 billion beat the consensus mark by 0.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. COR has a historical average earnings growth rate of 13.8% compared with the industry's 1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 6%. Veeva Systems, carrying a Zacks Rank #2 at present, posted first-quarter fiscal 2026 adjusted EPS of $1.97, exceeding the Zacks Consensus Estimate by 13.2%. Revenues of $759 million surpassed the Zacks Consensus Estimate by 4.3%. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 17.9% growth. The company's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10%. Resmed, currently carrying a Zacks Rank #2, reported third-quarter fiscal 2025 adjusted EPS of $2.30, which surpassed the Zacks Consensus Estimate by 0.4%. Revenues of $1.29 billion topped the Zacks Consensus Estimate by 0.5%. RMD has an estimated long-term earnings growth rate of 15.3% compared with the industry's 14% growth. The company's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 4.2%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Globe and Mail
a day ago
- Globe and Mail
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Thermo Fisher Scientific Inc. 's TMO second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs. GAAP EPS was $4.28, up 6% on a year-over-year basis. Following the earnings announcement, shares of TMO rose 7.7% in pre-market trading today. TMO's Q2 Revenues in Detail Revenues in the quarter increased 2.9% year over year to $10.85 billion. Moreover, the top line surpassed the Zacks Consensus Estimate by 1.9%. Organic revenues in the reported quarter increased 2% year over year. Thermo Fisher's Segmental Analysis Thermo Fisher operates under four business segments, as discussed below: Life Sciences Solutions Revenues in the Life Sciences Solutions segment (23% of total revenues) increased 6.1% year over year to $2.50 billion. The number surpassed our model's estimate of $2.37 billion. Analytical Instruments Revenues in this segment (15.9%) declined 3% year over year to $1.73 billion. The figure missed our model's estimate of $1.84 billion. Specialty Diagnostics Revenues in the Specialty Diagnostics segment (10.4%) increased 1.5% year over year to $1.13 billion. The number missed our model's prediction of $1.15 billion. Laboratory Products and Biopharma Services Revenues in this segment (55.2%) rose 4.1% year over year to $5.99 billion. Our model's estimate was $5.71 billion. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) TMO's Margin Performance Gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year due to a 4.4% increase in the cost of revenues. In the quarter, selling, general and administrative expenses rose 5.4% to $1.78 billion. Research and development expenses increased 3.8% to $352 million. The adjusted operating margin in the quarter was 21.6%, reflecting a contraction of 124 bps. Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise TMO's Financial Position The company ended the second quarter of 2025 with cash and cash equivalents and short-term investments of $6.39 billion compared with $5.95 billion at the end of the first quarter of 2025. Cumulative net cash from operating activities at the end of the second quarter was $2.12 billion compared with $3.21 billion a year ago. Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth of 14.86%. Our Take on Thermo Fisher Stock Thermo Fisher exited the second quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat the respective estimates. Barring the Analytical Instruments segment, all other business segments reported growth during the quarter. However, contraction of both margins in the quarter was discouraging. The company will provide its 2025 guidance on the earnings call today. During the second quarter, the company advanced in its growth strategy by launching a range of next-generation, high-impact, innovative instruments, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, the Thermo Scientific Orbitrap™ Excedion Pro mass spectrometer and the Thermo Scientific Krios 5 Cryo-TEM. These instruments help researchers deepen the understanding of complex diseases, advance precision medicine and enable the development of new therapies. In addition, TMO expanded the DynaDrive single-use bioreactor portfolio for drug production to include a new first-of-its-kind bench-scale system, enabling meaningful workflow efficiencies and seamless scale-up from the bench to commercialization. All these developments translated into meaningful commercial wins for the company in the second quarter, which is encouraging. TMO's Zacks Rank & Key Picks Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Veeva Systems VEEV and Boston Scientific BSX. Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. You can see the complete list of today's Zacks #1 Rank stocks here. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Veeva Systems, currently carrying a Zacks Rank #2 (Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Boston Scientific, carrying a Zacks Rank #2 at present, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report
